SCHEMBL3713752

SCHEMBL3713752

CCC(=O)Nc1ccc(C(=O)CN2C(=O)NC(CC)(c3ccc(Cl)cc3)C2=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.57
KMT2A Q03164 5/20 0.57
GAA P10253 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
MEN1 O00255 3/20 0.53
TDP1 Q9NUW8 1/20 0.52
USP2 O75604 1/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
KEAP1 Q14145 1/20 0.48
NFE2L2 Q16236 1/20 0.48
MAPT P10636 1/20 0.48
AKR1B1 P15121 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3663169 0.90 TSHR (0.59) FPR2KMT2ASMN1; SMN2MEN1TDP1
SCHEMBL3660710 0.90 KMT2A (0.66) FPR2KMT2AMEN1USP2CRHBP
SCHEMBL28788580 0.84 KMT2A (0.49) FPR2KMT2ASMN1; SMN2MEN1USP2
SCHEMBL3662076 0.81 KMT2A (0.55) KMT2AMEN1USP2CRHBPCRHR2
SCHEMBL3659945 0.81 TSHR (0.56) FPR2KMT2ASMN1; SMN2MEN1TDP1
SCHEMBL3659938 0.80 KMT2A (0.61) FPR2KMT2AMEN1USP2CRHBP
SCHEMBL3660498 0.80 KMT2A (0.61) FPR2KMT2AMEN1USP2CRHBP
SCHEMBL3658552 0.77 FPR2 (0.56) FPR2KMT2ASMN1; SMN2MEN1TDP1
SCHEMBL3655610 0.77 MEN1 (0.65) KMT2AMEN1TDP1POLB
SCHEMBL3658807 0.76 KMT2A (0.73) KMT2AMEN1AKR1B1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101827840-A Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators NOVARTIS AG 2010-09-08 CN claimed
EP-2212314-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS Novartis AG (CH) 2010-08-04 EP claimed
WO-2009050200-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS NOVARTIS AG (CH) 2009-04-23 WO claimed
US-20090099243-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US claimed
CN-101827840-A Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators NOVARTIS AG 2010-09-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099243-A1 ORGANIC COMPOUNDS SLCO4C1, SLCO1B1, SLCO1B3 FPR2 1224/4885KMT2A 2020/4885GAA 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.